almitrine
Sign in to saveAlso known as 2,4-bis(allylamino)-6-{4-[bis(p-fluorophenyl)methyl]-1-piperazinyl}-S-triazine
Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels a
Research
589 papers- Almitrine bismesylate.Drug intelligence & clinical pharmacy · 1987
- Almitrine-Raubasine combination for dementia.The Cochrane database of systematic reviews · 2011
- Hypoxia, almitrine, and peripheral neuropathy.Thorax · 1989
- Almitrine bismesylate.Zeitschrift fur Erkrankungen der Atmungsorgane · 1987
- Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?Anaesthesia, critical care & pain medicine · 2020
via PubMed
Wikidata facts
- Mass
- 477.24525
Show 5 more facts
- chemical formula
- C₂₆H₂₉F₂N₇
- canonical SMILES
- C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
- World Health Organisation international non-proprietary name
- almitrine
- defined daily dose
- 0.1
- Commons category
- Almitrine
Sources (3)
via Wikidata · CC0
~2 min read
Article
2 sectionsContents
- See also
- References
Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.
The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer. They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.